Trial · NCT02474355
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Osimertinib | 22.8 | 95% Confidence Interval 21.6 to 23.8 | Months | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AE of special interest (AESI) or SAE | 923 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AESI or SAE a causally related to Osimertinib | 338 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AE leading to dose modification | 414 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AE leading to discontinuation | 191 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AESI | 113 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AESI causally related to Osimertinib | 89 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | SAE | 657 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | SAE causally related to Osimertinib | 95 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AE leading to death | 152 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Osimertinib | AE leading to death causally related to Osimertinib | 19 | Participants | |
| Progression Free Survival | Osimertinib | 11.1 | 95% Confidence Interval 11.0 to 12.0 | Months | |
| Time to Treatment Discontinuation (TTD) | Osimertinib | 13.5 | 95% Confidence Interval 12.6 to 13.9 | Months | |
| Response Rate (RR) | Osimertinib | 57.3 | 95% Confidence Interval 55.5 to 59.2 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02474355/results